1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 55,23 | 55,57 | 20.10. | |
| 54,84 | 55,95 | 20.10. |
► 20.10.: | | | | | | | | |
► 19.10.: | | | | | | | | | 17:30
► Aktueller ROYALTY PHARMA Börsenkurs + Xetra-Orderbuch
► 19.10.: | | | | | | | | | 17:30
► Aktueller ROYALTY PHARMA Börsenkurs + Xetra-Orderbuch
| Stück | Geld | Kurs | Brief | Stück |
|---|---|---|---|---|
| 56,58 | 930 | |||
| 56,22 | 9 | |||
| 56,20 | 9 | |||
| 56,18 | 9 | |||
| 56,17 | 930 | |||
| 56,00 | 93 | |||
| 55,41 | 930 | |||
| 55,09 | 273 | |||
| 55,08 | 180 | |||
| 55,07 | 344 | |||
Quelle: [URL] https://aktienkurs-orderbuch.finanznachrichten.de/rpd.htm [/URL] | ||||
| 344 | 54,89 | |||
| 344 | 54,87 | |||
| 274 | 54,86 | |||
| 164 | 54,85 | |||
| 930 | 54,56 | |||
| 930 | 54,12 | |||
| 93 | 54,02 | |||
| 9 | 53,77 | |||
| 9 | 53,75 | |||
| 9 | 53,73 | |||
| Summe Aktien im Kauf | Verhältnis | Summe Aktien im Verkauf | ||
| 3.106 | 1,193 | 3.707 | ||
| Uhrzeit | Aktienkurs | Stück |
|---|---|---|
Keine Umsätze verfügbar. | ||
| Tagesumsatz Xetra | +1,31 +2,44 % | 0 |
Angaben in grüner Schrift zeigen, dass der Aktienkurs im Vergleich zum vorherigen Kurs gestiegen ist. Angaben in roter Schrift zeigen gefallene Börsenkurse.
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Fr | Royalty Pharma declares $0.235 dividend | 7 | Seeking Alpha | ||
| ROYALTY PHARMA Aktie jetzt für 0€ handeln | |||||
| Fr | Royalty Pharma declares $0.235 Q4 dividend, payable Dec. 10 | 6 | Investing.com | ||
| Fr | Royalty Pharma plc: Royalty Pharma declares fourth quarter 2026 dividend | 4 | GlobeNewswire (USA) | ||
| Do | If You Invested $1000 In Royalty Pharma Stock 15 Years Ago, You Would Have This Much Today | 2 | Benzinga.com | ||
| 09.10. | Royalty Pharma plc: Royalty Pharma to announce third quarter 2026 financial results on November 4, 2026 | 5 | GlobeNewswire (USA) |
1 2 3 4 5 Weiter >>
83 Nachrichten in den letzten 12 Monaten
| Zeit | Aktuelle Nachrichten | Medien | ||
|---|---|---|---|---|
| Di | Herbal Dispatch Inc.: Herbal Dispatch Expands Offering with New Ontario and Saskatchewan Listings and Increased BC Portfolio | Newsfile | Vancouver, British Columbia--(Newsfile Corp. - October 20, 2026) - Herbal Dispatch Inc. (CSE: HERB) (OTCQB: LUFFF) (FSE: HA9) ("Herbal Dispatch" or the "Company"), a cannabis commerce and international... ► Artikel lesen | |
| Di | Cosmos Health Inc.: Cosmos Health CEO Greg Siokas Issues Letter to Shareholders Highlighting Record 2026 Revenue, U.S. Subscription Growth and Global Expansion | ACCESS Newswire | Key HighlightsRecord revenue: preliminary nine-month 2026 revenue of approximately $54.3 million, up 19%, with every quarter of 2026 setting a record2026 outlook reaffirmed: full-year revenue expected... ► Artikel lesen | |
| Di | Hengrui Pharma Previews ESMO Congress 2026 with 64 Research Findings Across Its Innovative Oncology Portfolio | PR Newswire | Hengrui Pharma Previews ESMO Congress 2026 with 64 Research Findings Across Its Innovative Oncology Portfolio
64 findings accepted, including three Proffered Paper and three Rapid Oral presentations... ► Artikel lesen | |
| Di | AstraZeneca's Tezspire Shows Sustained Benefits In Phase 3 Esophagitis Trial | AFX News | LONDON (dpa-AFX) - AstraZeneca (AZN) said Tuesday that full results from the Phase 3 CROSSING trial showed Tezspire improved disease remission and swallowing symptoms in adolescents and adults... ► Artikel lesen | |
| Di | AbbVie's SKYRIZI Gets Health Canada Approval For Children With Moderate To Severe Plaque Psoriasis | AFX News | OTTAWA (dpa-AFX) - Drugmaker AbbVie Inc. (ABBV) announced Tuesday that Health Canada has approved SKYRIZI (risankizumab) to treat children with moderate to severe plaque psoriasis.The treatment... ► Artikel lesen |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ROYALTY PHARMA PLC finden Sie auf Wallstreet Online.